Concert Pharmaceuticals Inc. (CNCE) had a good day on the market for Tuesday January 05
shares jumped 2.99% to close at $13.07. About 307,070 shares traded hands on 2,565 trades for the day, compared with an average daily volume of
n/a shares out of a total float of 30.65 million. After opening the trading day at $12.60, shares of Concert Pharmaceuticals Inc. stayed within a range of $13.29 to
With today’s gains, Concert Pharmaceuticals Inc. now has a market cap of
$400.59 million. Shares of Concert Pharmaceuticals Inc. have been trading within a range of $13.50
and $5.47 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop small-molecule drugs by incorporating new elements into known molecules or by leveraging the current approved drugs to be used for new treatments. The pipeline consists of small molecules designed for oral administration to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer’s agitation.
Concert Pharmaceuticals Inc. is based out of Lexington, MA and has some 70 employees. Its CEO is Roger D. Tung.
For a complete fundamental analysis of Concert Pharmaceuticals Inc., check out Equities.com’s Stock Valuation Analysis report for
Still paying commissions on stock trades? Equities.com now offers $7.99/month unlimited trading and flat-fee options trading for $89.99/month! Get started today by https://www.equities.com/trading-start
Concert Pharmaceuticals Inc. is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell
Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an
objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives
a broad, unbiased look at the small-cap market as a whole.
To get more information on Concert Pharmaceuticals Inc. and to follow the company’s latest updates, you can visit the company’s profile page here:
CNCE’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s
Newsdesk. Also, don’t forget to sign-up for our daily
email newsletter to ensure you don’t miss out on any of our best stories.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.
The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer